Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
NVDQ's Cash to Debt is ranked higher than
90% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. NVDQ: No Debt )
NVDQ' s 10-Year Cash to Debt Range
Min: 0.72   Max: No Debt
Current: No Debt

Equity to Asset 0.86
NVDQ's Equity to Asset is ranked higher than
92% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. NVDQ: 0.86 )
NVDQ' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.97
Current: 0.86

-0.16
0.97
F-Score: 4
Z-Score: 18.72
M-Score: -0.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -35.57
NVDQ's Operating margin (%) is ranked higher than
62% of the 247 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. NVDQ: -35.57 )
NVDQ' s 10-Year Operating margin (%) Range
Min: -1277.65   Max: -13.33
Current: -35.57

-1277.65
-13.33
Net-margin (%) -21.65
NVDQ's Net-margin (%) is ranked higher than
63% of the 247 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. NVDQ: -21.65 )
NVDQ' s 10-Year Net-margin (%) Range
Min: -1102.23   Max: -53.7
Current: -21.65

-1102.23
-53.7
ROE (%) -6.30
NVDQ's ROE (%) is ranked higher than
67% of the 225 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. NVDQ: -6.30 )
NVDQ' s 10-Year ROE (%) Range
Min: -1836.38   Max: -21.98
Current: -6.3

-1836.38
-21.98
ROA (%) -5.09
NVDQ's ROA (%) is ranked higher than
68% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. NVDQ: -5.09 )
NVDQ' s 10-Year ROA (%) Range
Min: -93.16   Max: -16.86
Current: -5.09

-93.16
-16.86
ROC (Joel Greenblatt) (%) -73.28
NVDQ's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. NVDQ: -73.28 )
NVDQ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3430.5   Max: -33.94
Current: -73.28

-3430.5
-33.94
Revenue Growth (%) 14.50
NVDQ's Revenue Growth (%) is ranked higher than
92% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. NVDQ: 14.50 )
NVDQ' s 10-Year Revenue Growth (%) Range
Min: -7.5   Max: 149.3
Current: 14.5

-7.5
149.3
EBITDA Growth (%) 0.80
NVDQ's EBITDA Growth (%) is ranked higher than
72% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. NVDQ: 0.80 )
NVDQ' s 10-Year EBITDA Growth (%) Range
Min: -32   Max: 67.7
Current: 0.8

-32
67.7
EPS Growth (%) -0.20
NVDQ's EPS Growth (%) is ranked higher than
74% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.50 vs. NVDQ: -0.20 )
NVDQ' s 10-Year EPS Growth (%) Range
Min: -27   Max: 64.3
Current: -0.2

-27
64.3
» NVDQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NVDQ Guru Trades in Q4 2013

Ron Baron 13,330 sh (New)
Chuck Royce 135,000 sh (unchged)
» More
Q1 2014

NVDQ Guru Trades in Q1 2014

Ron Baron 19,280 sh (+44.64%)
Chuck Royce 120,000 sh (-11.11%)
» More
Q2 2014

NVDQ Guru Trades in Q2 2014

Chuck Royce 60,000 sh (-50%)
Ron Baron 4,680 sh (-75.73%)
» More
Q3 2014

NVDQ Guru Trades in Q3 2014

Steven Cohen 130,400 sh (New)
Ron Baron 47,400 sh (+912.82%)
Chuck Royce 60,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NVDQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-09-30 Add 912.82%$12.45 - $17.16 $ 14.39-1%47400
Ron Baron 2014-06-30 Reduce -75.73%$13.71 - $23.61 $ 14.39-13%4680
Ron Baron 2014-03-31 Add 44.64%$16.36 - $22.97 $ 14.39-27%19280
Ron Baron 2013-12-31 New Buy$15.67 - $18.719 $ 14.39-13%13330
Prem Watsa 2013-06-30 Sold Out 0.87%$9.93 - $14.76 $ 14.3912%0
Prem Watsa 2013-03-31 Add 17.92%0.13%$8.74 - $11.42 $ 14.3948%2358487
Prem Watsa 2012-12-31 New Buy0.69%$8.42 - $11.94 $ 14.3944%2000000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.48
NVDQ's P/B is ranked higher than
69% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.45 vs. NVDQ: 4.48 )
NVDQ' s 10-Year P/B Range
Min: 0.82   Max: 274
Current: 4.48

0.82
274
P/S 18.18
NVDQ's P/S is ranked higher than
58% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. NVDQ: 18.18 )
NVDQ' s 10-Year P/S Range
Min: 1.6   Max: 491
Current: 18.18

1.6
491
EV-to-EBIT -41.56
NVDQ's EV-to-EBIT is ranked lower than
58% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NVDQ: -41.56 )
NVDQ' s 10-Year EV-to-EBIT Range
Min: -281.9   Max: -0.7
Current: -41.56

-281.9
-0.7
Current Ratio 22.59
NVDQ's Current Ratio is ranked higher than
99% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.55 vs. NVDQ: 22.59 )
NVDQ' s 10-Year Current Ratio Range
Min: 1   Max: 26.52
Current: 22.59

1
26.52
Quick Ratio 21.81
NVDQ's Quick Ratio is ranked higher than
98% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. NVDQ: 21.81 )
NVDQ' s 10-Year Quick Ratio Range
Min: 0.85   Max: 26.46
Current: 21.81

0.85
26.46

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.17
NVDQ's Price/Net Cash is ranked higher than
92% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NVDQ: 6.17 )
NVDQ' s 10-Year Price/Net Cash Range
Min: 5.35   Max: 63.75
Current: 6.17

5.35
63.75
Price/Net Current Asset Value 5.57
NVDQ's Price/Net Current Asset Value is ranked higher than
91% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NVDQ: 5.57 )
NVDQ' s 10-Year Price/Net Current Asset Value Range
Min: 4.83   Max: 106.67
Current: 5.57

4.83
106.67
Price/Tangible Book 4.84
NVDQ's Price/Tangible Book is ranked higher than
77% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.49 vs. NVDQ: 4.84 )
NVDQ' s 10-Year Price/Tangible Book Range
Min: 2.73   Max: 455
Current: 4.84

2.73
455
Price/Median PS Value 1.41
NVDQ's Price/Median PS Value is ranked higher than
67% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.34 vs. NVDQ: 1.41 )
NVDQ' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 36.54
Current: 1.41

0.16
36.54
Earnings Yield (Greenblatt) -2.40
NVDQ's Earnings Yield (Greenblatt) is ranked higher than
68% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NVDQ: -2.40 )
NVDQ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -2.4

Forward Rate of Return (Yacktman) -12.59
NVDQ's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. NVDQ: -12.59 )
NVDQ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -25.9   Max: -8.5
Current: -12.59

-25.9
-8.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:NDQ.Canada, NQT.Germany
Novadaq Technologies Inc was incorporated under the Canada Business Corporations Act on April 14, 2000. The Company develops and commercializes medical imaging and therapeutic devices for use in the operating room. It's imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company's business activities are conducted through one segment, which consists of medical devices. Its product includes, SPY Elite, PINPOINT Endoscopic Fluorescence Imaging, FIREFLY System for Robotic Surgery, LUNA Fluorescence Angiography and CO2 HEART LASER System. The SPY Imaging System provides clinically relevant information that empowers surgeons to make informed critical decisions in the operating room. PINPOINT Endoscopic Fluorescence Imaging System combines all of the fluorescence imaging capabilities of SPY Imaging with the HD visible light imaging capabilities of a traditional endoscopic imaging system. FIREFLY system enables surgeons performing robotic surgery to benefit from fluorescence imaging, with initial use in applications ranging from urology to gynecology. LUNA fluorescence angiography enables clinicians to visually assess tissue perfusion in diabetic foot ulcers and non-healing wounds. The CO2 HEART LASER System consists of: the CO2 HEART LASER mobile console and the CO2 HEART LASER disposable hand pieces. The Company's intellectual property consists of 49 patent families representing 128 granted or allowed patents and 90 pending applications in various stages of review and prosecution.
» More Articles for NVDQ

Headlines

Articles On GuruFocus.com
Prem Watsa Increases NYT and Two Others May 15 2013 
comment on NVDQ Mar 03 2013 
Prem Watsa Increases Novadaq Technologies Ownership to 6.6 Pct Feb 14 2013 

More From Other Websites
Novadaq Technologies (NVDQ) Shares March Higher, Can It Continue? Nov 10 2014
Novadaq misses 3Q profit forecasts Nov 06 2014
Novadaq misses 3Q profit forecasts Nov 06 2014
NOVADAQ Reports Third Quarter 2014 Financial Results Nov 06 2014
NOVADAQ Reports Third Quarter 2014 Financial Results Nov 06 2014
Novadaq Technologies (NVDQ) Weak On High Volume Nov 03 2014
NOVADAQ Announces Transfer of SPY(R) Elite Business From LifeCell Corporation Oct 30 2014
NOVADAQ to Participate in Healthcare November Investor Conferences Oct 27 2014
NOVADAQ to Participate in November Investor Healthcare Conferences Oct 27 2014
NOVADAQ Appoints Mizuho Medical as PINPOINT Distributor for Japan Mizuho to exclusively represent... Oct 21 2014
NOVADAQ Appoints Mizuho Medical as PINPOINT Distributor for Japan Oct 21 2014
NOVADAQ to Release Third Quarter 2014 Financial Results on November 6, 2014 – Conference Call to... Oct 17 2014
NOVADAQ to Release Third Quarter 2014 Financial Results on November 6, 2014 -- Conference Call to... Oct 17 2014
Profound Medical Appoints Dr. Arun Menawat to Board of Directors Oct 17 2014
NOVADAQ Appoints Kirloskar Technologies As Its Exclusive Distributor in India Canadian Minister of... Oct 16 2014
NOVADAQ Appoints Kirloskar Technologies as Its Exclusive Distributor in India Oct 16 2014
5 Stocks Spiking on Unusual Volume Oct 02 2014
Novadaq PINPOINT Studies Published in JACS and Annals of Surgery Oct 02 2014
NOVADAQ Announces Multi-Unit Agreement With SerenaGroup for LUNA Sep 30 2014
NOVADAQ to Host Analyst & Investor Day on November 17, 2014 Sep 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK